PF-1355 是一种有效的 MPO 抑制剂。PF-1355用于血管炎的研究。

PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor. PF-1355 is used for treatment of vasculitic diseases.

PF-1355 inhibits MPO activity in phorbol ester-stimulated human neutrophils as measured by taurine chlorination (EC50=1.47 μM) as well as lipopolysaccharide-treated human blood measuring residual MPO activity (EC50=2.03 μM) [1].

Oral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment [1].

1435467-38-1

C14H15N3O4S

321.35

PF 06281355;ZINC205721785;PF-06281355

DMSO:40 mg/mL (124.5 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years